Examining medicine shortages and their consequences through economic, clinical, and economic lens
A study on medicine shortages in the Netherlands found that disease and costs were the two most affected elements, with 30% and 20% of shortages rated high on these elements, respectively. The study used a framework of economic, clinical, and patient outcomes to assess the impact of medicine shortages on patients. Direct impact, represented by alternative product and disease, was rated high for 30% of the shortages, while indirect impact, represented by costs, susceptibility, and number of patients, was rated high for 17% of the shortages. No significant differences in impact scores were found based on product characteristics.
Recent Posts
Belgium Fast Access Medicines Revolutionize Treatment for IgA Nephropathy
Belgium Fast Access Medicines has moved from policy to practice. Authorities have granted temporary reimbursement to Atrasentan, the first therapy approved under the new Early and Equitable Fast Access procedure, offering quicker hope to patients with IgA nephropathy while anchoring the country’s...
Retracted Trial Publication Undermines Support for Avacopan in AAV Treatment
The Retracted Trial Publication of the ADVOCATE study has eliminated the central evidence that supported approval of Tavneos (avacopan) for severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV). At the request of two lead academic authors, the
Advancing Regulatory Validation Taletrectinib for Enhanced NSCLC Treatment
The MHRA’s validation of Nuvation Bio’s marketing authorisation application marks an important regulatory validation taletrectinib for adults with advanced ROS1-positive non-small cell lung cancer. This milestone, achieved via the International Recognition Procedure in parallel with EMA review, f...